Archives of Critical Care Medicine

Published by: Kowsar

The Relationship Between Changes in Liver Enzymes and Mortality of Patients Admitted to a Surgical Intensive Care Unit

Omid Moradi Moghaddam 1 , Mahzad Alimian 2 , * , Mohammad Niakan Lahiji 1 , Valiollah Hasani 3 and Ali Ahani Azari 4
Authors Information
1 Assistant Professor of Anesthesiology and Critical Care department, Rasool-e-Akram Complex Hospital, Trauma and Injury Research Center, Iran University of Medical Sciences, Tehran, IR Iran
2 Assistant Professor of Anesthesiology and Pain Department, Rasool-e-Akram Complex Hospital, Iran University of Medical Sciences, Tehran, IR Iran
3 Professor of Anesthesiology and Pain Department, Rasool-e-Akram Complex Hospital, Iran University of Medical Sciences, Tehran, IR Iran
4 Resident of Anesthesiology and Pain Department, Rasool-e-Akram Complex Hospital, Iran University of Medical Sciences, Tehran, IR Iran
Article information
  • Archives of Critical Care Medicine: February 2016, 2 (1); e55433
  • Published Online: January 31, 2016
  • Article Type: Research Article
  • Received: December 6, 2015
  • Accepted: January 5, 2016
  • DOI: 10.5812/accm-55433
EIC Notes

همكارا گرامي

 با سلام

احتراما نويسنده مسئول مقاله حاضر به شرح ذيل تغيير مي‌يابد.

آقای دکتر مهزاد علیمیان

با تشكر

To Cite: Moradi Moghaddam O, Alimian M, Niakan Lahiji M, Hasani V, Ahani Azari A. The Relationship Between Changes in Liver Enzymes and Mortality of Patients Admitted to a Surgical Intensive Care Unit, Arch Crit Care Med. 2016 ; 2(1):e55433. doi: 10.5812/accm-55433.

Copyright © 2016, Archives of Critical Care Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349(5):474-85. doi: 10.1056/NEJMra021844. [PubMed: 12890847].
  • 2. Thomson SJ, Cowan ML, Johnston I, Musa S, Grounds M, Rahman TM. 'Liver function tests' on the intensive care unit: a prospective, observational study. Intensive Care Med. 2009;35(8):1406-11. doi: 10.1007/s00134-009-1511-7. [PubMed: 19513695].
  • 3. Dancygier H. Clinical hepatology: Principles and practice of hepatobiliary diseases. 2. Springer Science & Business Media; 2009.
  • 4. Field E, Horst HM, Rubinfeld IS, Copeland CF, Waheed U, Jordan J, et al. Hyperbilirubinemia: a risk factor for infection in the surgical intensive care unit. Am J Surg. 2008;195(3):304-6. discussion 306-7. doi: 10.1016/j.amjsurg.2007.12.010. [PubMed: 18206848].
  • 5. Brienza N, Dalfino L, Cinnella G, Diele C, Bruno F, Fiore T. Jaundice in critical illness: promoting factors of a concealed reality. Intensive Care Med. 2006;32(2):267-74. doi: 10.1007/s00134-005-0023-3. [PubMed: 16450099].
  • 6. Kramer L, Jordan B, Druml W, Bauer P, Metnitz PG, Austrian Epidemiologic Study on Intensive Care ASG. Incidence and prognosis of early hepatic dysfunction in critically ill patients--a prospective multicenter study. Crit Care Med. 2007;35(4):1099-104. doi: 10.1097/01.CCM.0000259462.97164.A0. [PubMed: 17334250].
  • 7. Mesotten D, Wauters J, Van den Berghe G, Wouters PJ, Milants I, Wilmer A. The effect of strict blood glucose control on biliary sludge and cholestasis in critically ill patients. J Clin Endocrinol Metab. 2009;94(7):2345-52. doi: 10.1210/jc.2008-2579. [PubMed: 19366849].
  • 8. Harbrecht BG, Doyle HR, Clancy KD, Townsend RN, Billiar TR, Peitzman AB. The impact of liver dysfunction on outcome in patients with multiple injuries. Am Surg. 2001;67(2):122-6. [PubMed: 11243533].
  • 9. Wiegand BD, Ketterer SG, Rapaport E. The use of indocyanine green for the evaluation of hepatic function and blood flow in man. Am J Dig Dis. 1960;5:427-36. [PubMed: 13844597].
  • 10. Sakka SG, Reinhart K, Meier-Hellmann A. Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest. 2002;122(5):1715-20. [PubMed: 12426276].
  • 11. Kimura S, Yoshioka T, Shibuya M, Sakano T, Tanaka R, Matsuyama S. Indocyanine green elimination rate detects hepatocellular dysfunction early in septic shock and correlates with survival. Crit Care Med. 2001;29(6):1159-63. [PubMed: 11395594].
  • 12. Koch A, Horn A, Duckers H, Yagmur E, Sanson E, Bruensing J, et al. Increased liver stiffness denotes hepatic dysfunction and mortality risk in critically ill non-cirrhotic patients at a medical ICU. Crit Care. 2011;15(6):R266. doi: 10.1186/cc10543. [PubMed: 22082207].
  • 13. Henrion J, Schapira M, Luwaert R, Colin L, Delannoy A, Heller FR. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore). 2003;82(6):392-406. doi: 10.1097/ [PubMed: 14663289].
  • 14. Raurich JM, Perez O, Llompart-Pou JA, Ibanez J, Ayestaran I, Perez-Barcena J. Incidence and outcome of ischemic hepatitis complicating septic shock. Hepatol Res. 2009;39(7):700-5. doi: 10.1111/j.1872-034X.2009.00501.x. [PubMed: 19473435].
  • 15. Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M, Bojic A, et al. Impact of hypoxic hepatitis on mortality in the intensive care unit. Intensive Care Med. 2011;37(8):1302-10. doi: 10.1007/s00134-011-2248-7. [PubMed: 21647720].
  • 16. Pastor CM, Suter PM. Hepatic hemodynamics and cell functions in human and experimental sepsis. Anesth Analg. 1999;89(2):344-52. [PubMed: 10439746].
  • 17. Geier A, Fickert P, Trauner M. Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(10):574-85. doi: 10.1038/ncpgasthep0602. [PubMed: 17008927].
  • 18. Kortgen A, Paxian M, Werth M, Recknagel P, Rauchfuss F, Lupp A, et al. Prospective assessment of hepatic function and mechanisms of dysfunction in the critically ill. Shock. 2009;32(4):358-65. doi: 10.1097/SHK.0b013e31819d8204. [PubMed: 19197231].
  • 19. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22(2):145-55. doi: 10.1055/s-2002-30105. [PubMed: 12016546].
  • 20. Lat I, Foster DR, Erstad B. Drug-induced acute liver failure and gastrointestinal complications. Crit Care Med. 2010;38(6 Suppl):S175-87. doi: 10.1097/CCM.0b013e3181de0db2. [PubMed: 20502172].
  • 21. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731-9. doi: 10.1056/NEJMra052270. [PubMed: 16481640].
  • 22. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55-68. doi: 10.2165/00002018-200932010-00005. [PubMed: 19132805].
  • 23. Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet. 2010;376(9736):190-201. doi: 10.1016/S0140-6736(10)60274-7. [PubMed: 20638564].
  • 24. Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl. 2009;15(7):719-29. doi: 10.1002/lt.21692. [PubMed: 19562705].
  • 25. Carter BA, Shulman RJ. Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2007;4(5):277-87. doi: 10.1038/ncpgasthep0796. [PubMed: 17476210].
  • 26. Grau T, Bonet A, Rubio M, Mateo D, Farre M, Acosta JA, et al. Liver dysfunction associated with artificial nutrition in critically ill patients. Crit Care. 2007;11(1):R10. doi: 10.1186/cc5670. [PubMed: 17254321].
  • 27. Sy E, Ronco JJ, Searle R, Karvellas CJ. Prognostication of critically ill patients with acute-on-chronic liver failure using the Chronic Liver Failure-Sequential Organ Failure Assessment: A Canadian retrospective study. J Crit Care. 2016;36:234-9. doi: 10.1016/j.jcrc.2016.08.003. [PubMed: 27569253].
  • 28. Ambrosy AP, Gheorghiade M, Bubenek S, Vinereanu D, Vaduganathan M, Macarie C, et al. The predictive value of transaminases at admission in patients hospitalized for heart failure: findings from the RO-AHFS registry. Eur Heart J Acute Cardiovasc Care. 2013;2(2):99-108. doi: 10.1177/2048872612474906. [PubMed: 24222818].
  • 29. Yeo CD, Kim JW, Kim SC, Kim YK, Kim KH, Kim HJ, et al. Prognostic factors in critically ill patients with hematologic malignancies admitted to the intensive care unit. J Crit Care. 2012;27(6):739 e1-6. doi: 10.1016/j.jcrc.2012.07.014. [PubMed: 23217573].
  • 30. Shteyer E, Yatsiv I, Sharkia M, Milgarter E, Granot E. Serum transaminases as a prognostic factor in children post cardiac surgery. Pediatr Int. 2011;53(5):725-8. doi: 10.1111/j.1442-200X.2011.03356.x. [PubMed: 21410598].
  • 31. Raurich JM, Llompart-Pou JA, Ferreruela M, Colomar A, Molina M, Royo C, et al. Hypoxic hepatitis in critically ill patients: incidence, etiology and risk factors for mortality. J Anesth. 2011;25(1):50-6. doi: 10.1007/s00540-010-1058-3. [PubMed: 21153035].
  • 32. Lazzeri C, Valente S, Tarquini R, Chiostri M, Picariello C, Gensini GF. Prognostic values of admission transaminases in ST-elevation myocardial infarction submitted to primary angioplasty. Med Sci Monit. 2010;16(12):CR567-74. [PubMed: 21119573].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments